December 5, 2017 / 12:43 PM / 13 days ago

BRIEF-Actinium Pharmaceuticals Says Phase 2 Clinical Trial Planned For 2018 For Actimab-MDS​

Dec 5 (Reuters) - Actinium Pharmaceuticals Inc:

* ACTINIUM PHARMACEUTICALS UNVEILS ACTIMAB-MDS AND PLANNED PHASE 2 TRIAL IN MYELODYSPLASTIC SYNDROMES TARGETED AT PATIENTS WITH HIGH-RISK P53+ GENETIC MUTATIONS

* SAYS ‍PHASE 2 CLINICAL TRIAL PLANNED FOR 2018 FOR ACTIMAB-MDS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below